Randomized Study of Individualized Care Plans for Hematopoietic Cell Transplant Survivors

Overview

About this study

This randomized study will compare a personalized Survivorship Care Plan (SCP) template with usual care (no SCP). The investigators hypothesize that the personalized SCP that incorporates patient specific treatment exposures and provides a framework for long term followup based on those exposures and subsequent risks for late complications will enhance patient survivorship confidence in knowledge, increase adherence to recommended healthcare, improve health behaviors and reduce HCT-related emotional distress.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Adult (≥ 18 years at time of allogeneic HCT recipient at participating transplant centers)
Survival 1-2 years after most recent HCT with no evidence of relapse, disease progression, or secondary cancer on last follow-up
All diagnoses will be eligible
All transplant types will be eligible (autologous or allogeneic related or unrelated)
All graft sources will be eligible (bone marrow, peripheral blood or umbilical cord blood)
All conditioning regimens will be eligible (in case of allogeneic HCT, patient could have received myeloablative or non-myeloablative/reduced-intensity conditioning)
Patient may have received more than one HCT
Patient must be proficient in English (written and spoken) to complete study assessments
Patient must have a valid mailing address within the United States to receive study materials
Signed informed consent form from patient

Exclusion Criteria:

Patients who have received their transplant at a different transplant center will not be eligible for the study

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator William Hogan, M.B., B.Ch.	Closed for enrollment	Contact information: Cancer Center Clinical Trials Referral Office 855-776-0015
Scottsdale/Phoenix, Ariz. Mayo Clinic principal investigator Nandita Khera, M.D., M.P.H.	Closed for enrollment	Contact information: Cancer Center Clinical Trials Referral Office 855-776-0015

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

William Hogan, M.B., B.Ch.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Nandita Khera, M.D., M.P.H.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

More information

Publications

Publications are currently not available

Clinical Trials